This HTML5 document contains 145 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n14http://linked.opendata.cz/resource/drugbank/drug/DB00176/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00176/identifier/national-drug-code-directory/
foafhttp://xmlns.com/foaf/0.1/
n28http://linked.opendata.cz/resource/mesh/concept/
n9http://linked.opendata.cz/resource/drugbank/company/
n7http://linked.opendata.cz/resource/drugbank/dosage/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00176/identifier/chemspider/
n24http://bio2rdf.org/drugbank:
n17http://linked.opendata.cz/resource/drugbank/drug/DB00176/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n30http://www.rxlist.com/cgi/generic/
n26http://linked.opendata.cz/resource/drugbank/patent/
n5http://linked.opendata.cz/resource/drugbank/drug/DB00176/identifier/wikipedia/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00176/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00176/identifier/kegg-compound/
n27http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n20http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
n29http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00176/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00176/identifier/pubchem-substance/
n16http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00176
rdf:type
n3:Drug
n3:description
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
n3:dosage
n7:271B51A9-363D-11E5-9242-09173F13E4C5 n7:271B51AA-363D-11E5-9242-09173F13E4C5 n7:271B51AB-363D-11E5-9242-09173F13E4C5 n7:271B51AC-363D-11E5-9242-09173F13E4C5 n7:271B51AD-363D-11E5-9242-09173F13E4C5 n7:271B51AE-363D-11E5-9242-09173F13E4C5 n7:271B51AF-363D-11E5-9242-09173F13E4C5 n7:271B51B0-363D-11E5-9242-09173F13E4C5 n7:271B51B1-363D-11E5-9242-09173F13E4C5 n7:271B51B2-363D-11E5-9242-09173F13E4C5 n7:271B51B3-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Dell'Osso B, Allen A, Hollander E: Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin Pharmacother. 2005 Dec;6(15):2727-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16316311 # Irons J: Fluvoxamine in the treatment of anxiety disorders. Neuropsychiatr Dis Treat. 2005 Dec;1(4):289-99. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18568110
n3:group
investigational approved
n3:halfLife
15.6 hours
n3:indication
For management of depression and for Obsessive Compulsive Disorder (OCD). Has also been used in the management of bulimia nervosa.
n3:manufacturer
n9:271B518D-363D-11E5-9242-09173F13E4C5 n9:271B5184-363D-11E5-9242-09173F13E4C5 n9:271B518E-363D-11E5-9242-09173F13E4C5 n9:271B5185-363D-11E5-9242-09173F13E4C5 n9:271B5182-363D-11E5-9242-09173F13E4C5 n9:271B518C-363D-11E5-9242-09173F13E4C5 n9:271B5183-363D-11E5-9242-09173F13E4C5 n9:271B518A-363D-11E5-9242-09173F13E4C5 n9:271B518B-363D-11E5-9242-09173F13E4C5 n9:271B5188-363D-11E5-9242-09173F13E4C5 n9:271B5189-363D-11E5-9242-09173F13E4C5 n9:271B518F-363D-11E5-9242-09173F13E4C5 n9:271B5186-363D-11E5-9242-09173F13E4C5 n9:271B5187-363D-11E5-9242-09173F13E4C5 n9:271B5190-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00176 n24:DB00176
dcterms:title
Fluvoxamine
adms:identifier
n5:Fluvoxamine n12:C07571 n13:57664-357-88 n14:DB00176 n17:5138 n18:3287 n22:46507588 n23:PA449690 n25:5324346
n3:mechanismOfAction
The exact mechanism of action of fluvoxamine has not been fully determined, but appears to be linked to its inhibition of CNS neuronal uptake of serotonin. Fluvoxamine blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT<sub>1A</sub> autoreceptors. In-vitro studies suggest that fluvoxamine is more potent than clomipramine, fluoxetine, and desipramine as a serotonin-reuptake inhibitor. Studies have also demonstrated that fluvoxamine has virtually no affinity for α<sub>1</sub>- or α<sub>2</sub>-adrenergic, β-adrenergic, muscarinic, dopamine D<sub>2</sub>, histamine H<sub>1</sub>, GABA-benzodiazepine, opiate, 5-HT<sub>1</sub>, or 5-HT<sub>2</sub> receptors.
n3:packager
n9:271B516C-363D-11E5-9242-09173F13E4C5 n9:271B516D-363D-11E5-9242-09173F13E4C5 n9:271B516A-363D-11E5-9242-09173F13E4C5 n9:271B516B-363D-11E5-9242-09173F13E4C5 n9:271B5178-363D-11E5-9242-09173F13E4C5 n9:271B5179-363D-11E5-9242-09173F13E4C5 n9:271B5176-363D-11E5-9242-09173F13E4C5 n9:271B5177-363D-11E5-9242-09173F13E4C5 n9:271B517C-363D-11E5-9242-09173F13E4C5 n9:271B517D-363D-11E5-9242-09173F13E4C5 n9:271B517A-363D-11E5-9242-09173F13E4C5 n9:271B517B-363D-11E5-9242-09173F13E4C5 n9:271B5170-363D-11E5-9242-09173F13E4C5 n9:271B5171-363D-11E5-9242-09173F13E4C5 n9:271B516E-363D-11E5-9242-09173F13E4C5 n9:271B516F-363D-11E5-9242-09173F13E4C5 n9:271B5174-363D-11E5-9242-09173F13E4C5 n9:271B5175-363D-11E5-9242-09173F13E4C5 n9:271B5172-363D-11E5-9242-09173F13E4C5 n9:271B5173-363D-11E5-9242-09173F13E4C5 n9:271B5180-363D-11E5-9242-09173F13E4C5 n9:271B5181-363D-11E5-9242-09173F13E4C5 n9:271B517E-363D-11E5-9242-09173F13E4C5 n9:271B517F-363D-11E5-9242-09173F13E4C5
n3:patent
n26:7465462
n3:routeOfElimination
The main human metabolite was fluvoxamine acid which, together with its N-acetylated analog, accounted for about 60% of the urinary excretion products. Approximately 2% of fluvoxamine was excreted in urine unchanged. Following a 14C-labelled oral dose of fluvoxamine maleate (5 mg), an average of 94% of drug-related products was recovered in the urine within 71 hours.
n3:synonym
Fluvoxaminum Fluvoxamine Fluvoxamina
n3:toxicity
Side effects include anorexia, constipation, dry mouth, headache, nausea, nervousness, skin rash, sleep problems, somnolence, liver toxicity, mania, increase urination, seizures, sweating increase, tremors, or Tourette's syndrome.
n3:volumeOfDistribution
* 25 L/kg
n15:hasAHFSCode
n21:28-16-04-20
n3:foodInteraction
Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can significantly increase serum levels of this product. Take without regard to meals. Avoid alcohol. Avoid high doses of caffeine.
n3:proteinBinding
~77-80% (plasma protein)
n3:salt
n3:synthesisReference
Welle, H.B.A. and Claassen, V.; U.S. Patent 4,085,225; April 18, 1978; assigned to U.S. Phillips Corp.
n27:hasConcept
n28:M0025397
foaf:page
n20:fluvoxamine.html n29:flu1660.shtml n30:fluvox.htm
n3:IUPAC-Name
n6:271B51B8-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B51BE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B51BD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B51BA-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B51BB-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B51BC-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B51B6-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B51B4-363D-11E5-9242-09173F13E4C5 n6:271B51B7-363D-11E5-9242-09173F13E4C5 n6:271B51CE-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B51B5-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:N06AB08
n3:H-Bond-Acceptor-Count
n6:271B51C4-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B51C5-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B51BF-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B51C0-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B51C2-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B51C1-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B51C3-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed, bioavailability of fluvoxamine maleate is 53%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
54739-18-3
n3:category
n3:containedIn
n8:271B5193-363D-11E5-9242-09173F13E4C5 n8:271B5194-363D-11E5-9242-09173F13E4C5 n8:271B5191-363D-11E5-9242-09173F13E4C5 n8:271B5192-363D-11E5-9242-09173F13E4C5 n8:271B519F-363D-11E5-9242-09173F13E4C5 n8:271B51A0-363D-11E5-9242-09173F13E4C5 n8:271B519D-363D-11E5-9242-09173F13E4C5 n8:271B519E-363D-11E5-9242-09173F13E4C5 n8:271B51A3-363D-11E5-9242-09173F13E4C5 n8:271B51A4-363D-11E5-9242-09173F13E4C5 n8:271B51A1-363D-11E5-9242-09173F13E4C5 n8:271B51A2-363D-11E5-9242-09173F13E4C5 n8:271B5197-363D-11E5-9242-09173F13E4C5 n8:271B5198-363D-11E5-9242-09173F13E4C5 n8:271B5195-363D-11E5-9242-09173F13E4C5 n8:271B5196-363D-11E5-9242-09173F13E4C5 n8:271B519B-363D-11E5-9242-09173F13E4C5 n8:271B519C-363D-11E5-9242-09173F13E4C5 n8:271B5199-363D-11E5-9242-09173F13E4C5 n8:271B519A-363D-11E5-9242-09173F13E4C5 n8:271B51A7-363D-11E5-9242-09173F13E4C5 n8:271B51A8-363D-11E5-9242-09173F13E4C5 n8:271B51A5-363D-11E5-9242-09173F13E4C5 n8:271B51A6-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B51C9-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B51CB-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B51CC-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B51CD-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B51C8-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B51C7-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B51CA-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B51B9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B51C6-363D-11E5-9242-09173F13E4C5